Profound Medical Corp. to Release Fourth Quarter a

TORONTO, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V: PRN ) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, will announce its fourth quarter and full 2016 financial results after market close on Monday, March 6, 2017.

Profound CEO, Arun Menawat and VP of Finance, Rashed Dewan, will host a conference call at 5:00 p.m. ET to review the financial results and discuss business developments in the period.

Also on the call to provide first-hand insights on the use of TULSA-PRO ^® in clinical practice will be Dr. Joseph L. Chin, Chief of Surgical Oncology for the London Health Sciences Centre at Western University. Dr. Chin, a world-renowned urologist and researcher, served as the study principal investigator for the TULSA-PRO Phase I clinical trial and is also serving as the site principal investigator for the pivotal TACT trial. A Professor of Urology and Oncology at Western, Dr. Chin also serves as the Chair of the Surgical Oncology Division and Head of the Provincial Surgical Oncology Program for the Southwestern Ontario Region, and as the Chair of the Royal College of Physicians and Surgeons of Canada Specialty Committee in Urology.

Fourth Quarter and Full Year 2016 Results Conference Call Details:

The call will also be broadcast live and archived on the Company's website at profoundmedical.com under "Investor Presentations" in the Investor Relations section.

Profound is currently conducting a pilot commercial launch of TULSA-PRO in key European and other CE mark jurisdictions. The Company is also sponsoring a multicenter, prospective FDA-registered clinical trial, TACT, which is designed to further demonstrate the safety and effectiveness of this innovative technology.  If successful, TACT is expected to support Profound's application to the U.S. Food and Drug Administration for approval to market TULSA-PRO in the United States.

About Profound Medical Corp.

The Profound Medical team is committed to the effort to achieve a new therapeutic standard in prostate cancer. For the millions of men currently living with prostate cancer, and the thousands more who are diagnosed with it every year, current treatment options often mean having to make difficult choices based on potential side effects that can significantly impact quality of life.  Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate cancerous prostate tissue with precision, while actively protecting critical anatomy from potential side effects; a tomorrow where patients have access to a safe, fast and effective treatment option, so they can quickly return to their daily lives.

Established in 2008, Profound Medical is commercializing a novel technology, TULSA-PRO, which combines real-time Magnetic Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO is CE Marked and Profound is sponsoring a multicenter, prospective FDA-registered clinical trial, TACT.

Forward-Looking Statements

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact: Stephen Kilmer Investor Relations skilmer@profoundmedical.com T: 647.872.4849 Or Rashed Dewan Vice President, Finance T: 647-476-1350